D-serine and schizophrenia: an update (Q38031285)

27 August 2017

D-serine and schizophrenia: an update (English)

1 reference

27 August 2017

1 reference

1 reference

Emerson A Nunes

1

1 reference

27 August 2017

Erin M MacKenzie

2

1 reference

27 August 2017

David Rossolatos

3

1 reference

27 August 2017

Jorge Perez-Parada

4

1 reference

27 August 2017

Glen B Baker

5

1 reference

27 August 2017

Serdar M Dursun

6

1 reference

27 August 2017

1 July 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

7

1 reference

27 August 2017

801-812

1 reference

Historical development of the dopamine hypothesis of schizophrenia

27 August 2017

1 reference

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

All Psychotic Roads Lead to Increased Dopamine D2High Receptors: A Perspective

21 January 2018

1 reference

Psychosis pathways converge via D2high dopamine receptors

21 January 2018

1 reference

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

21 January 2018

1 reference

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

Testing the glutamate hypothesis of schizophrenia

21 January 2018

1 reference

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

21 January 2018

1 reference

Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia

21 January 2018

1 reference

N-methyl-D-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine

21 January 2018

1 reference

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

21 January 2018

1 reference

The NMDA antagonist MK-801 can impair attention to exteroceptive stimuli.

21 January 2018

1 reference

Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats

21 January 2018

1 reference

Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task

21 January 2018

1 reference

Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever-press counts.

21 January 2018

1 reference

Glycine transport accounts for the differential role of glycine vs. D-serine at NMDA receptor coagonist sites in the salamander retina

21 January 2018

1 reference

Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex.

21 January 2018

1 reference

Glia-derived D-serine controls NMDA receptor activity and synaptic memory

21 January 2018

1 reference

Preferred stereoselective brain uptake of d-serine--a modulator of glutamatergic neurotransmission

21 January 2018

1 reference

D-serine: the right or wrong isoform?

21 January 2018

1 reference

D-amino acids in the central nervous system in health and disease

21 January 2018

1 reference

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

Contributions of the D-serine pathway to schizophrenia.

21 January 2018

1 reference

The effects of a low protein diet on amino acids and enzymes in the serine synthesis pathway in mice

21 January 2018

1 reference

Metabolic control analysis of mammalian serine metabolism

21 January 2018

1 reference

Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission

21 January 2018

1 reference

Characterization and localization of a human serine racemase

21 January 2018

1 reference

Distribution and pharmacology of alanine–serine–cysteine transporter 1 (asc‐1) in rodent brain

21 January 2018

1 reference

Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids

21 January 2018

1 reference

Cloning and characterization of a human brain Na(+)-independent transporter for small neutral amino acids that transports D-serine with high affinity

21 January 2018

1 reference

Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS

21 January 2018

1 reference

Functional and immunocytochemical characterization of D-serine transporters in cortical neuron and astrocyte cultures

21 January 2018

1 reference

A novel alanine-insensitive D-serine transporter in rat brain synaptosomal membranes

21 January 2018

1 reference

Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-serine formation

21 January 2018

1 reference

Mutual regulation between serine and nitric oxide metabolism in human glioblastoma cells

21 January 2018

1 reference

Regulation of serine racemase activity by D-serine and nitric oxide in human glioblastoma cells

21 January 2018

1 reference

Feedback inactivation of D-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membrane

21 January 2018

1 reference

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

Glutamate signaling in the pathophysiology and therapy of schizophrenia

21 January 2018

1 reference

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

21 January 2018

1 reference

Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia

21 January 2018

1 reference

Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study.

21 January 2018

1 reference

Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients

21 January 2018

1 reference

Effects of low-dose D-serine on recognition and working memory in mice.

21 January 2018

1 reference

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.

21 January 2018

1 reference

Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801.

21 January 2018

1 reference

D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.

21 January 2018

1 reference

Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice.

21 January 2018

1 reference

Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.

21 January 2018

1 reference

Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior

21 January 2018

1 reference

Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology

21 January 2018

1 reference

The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex.

21 January 2018

1 reference

The reduced neuropil hypothesis: a circuit based model of schizophrenia.

21 January 2018

1 reference

Neuroplasticity of neocortical circuits in schizophrenia.

21 January 2018

1 reference

Brain derived neurotropic factor in first-episode psychosis

21 January 2018

1 reference

Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients.

21 January 2018

1 reference

Behavioral changes in G72/G30 transgenic mice.

21 January 2018

1 reference

Olfactory dysfunction in schizophrenia: a review of neuroanatomy and psychophysiological measurements

21 January 2018

1 reference

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

21 January 2018

1 reference

N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice

21 January 2018

1 reference

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors

21 January 2018

1 reference

The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.

21 January 2018

1 reference

In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties

21 January 2018

1 reference

Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.

21 January 2018

1 reference

Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors

21 January 2018

1 reference

Synthesis and biological evaluation of D-amino acid oxidase inhibitors.

21 January 2018

1 reference

Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia.

21 January 2018

1 reference

Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase.

21 January 2018

1 reference

Sensitive determination of D-amino acids in mammals and the effect of D-amino-acid oxidase activity on their amounts

21 January 2018

1 reference

Lack of the alanine-serine-cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice.

21 January 2018

1 reference

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine

21 January 2018

1 reference

Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase.

21 January 2018

1 reference

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

No changes in serum epidermal growth factor levels in patients with schizophrenia.

21 January 2018

1 reference

Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

21 January 2018

1 reference

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels

21 January 2018

1 reference

Serine racemase protein expression in cortex and hippocampus in schizophrenia

21 January 2018

1 reference

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

21 January 2018

1 reference

Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1).

21 January 2018

1 reference

Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia

21 January 2018

1 reference

Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia

21 January 2018

1 reference

Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study

21 January 2018

1 reference

Potential pathophysiological role of D-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain

21 January 2018

1 reference

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia.

21 January 2018

1 reference

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

21 January 2018

1 reference

Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios

21 January 2018

1 reference

Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis

21 January 2018

1 reference

Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance

21 January 2018

1 reference

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

21 January 2018

1 reference

Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.

21 January 2018

1 reference

pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility

21 January 2018

1 reference

Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function

21 January 2018

1 reference

The G72/G30 gene complex and cognitive abnormalities in schizophrenia.

21 January 2018

1 reference

A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe.

21 January 2018

1 reference

Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia.

21 January 2018

1 reference

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

21 January 2018

1 reference

Investigation of G72 (DAOA) expression in the human brain

21 January 2018

1 reference

Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample

21 January 2018

1 reference

Association of DAAO with schizophrenia in the Chinese population.

21 January 2018

1 reference

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

21 January 2018

1 reference

Association analysis of glycine- and serine-related genes in a Japanese population of patients with schizophrenia

21 January 2018

1 reference

No association of G72 and D-amino acid oxidase genes with schizophrenia

21 January 2018

1 reference

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

21 January 2018

1 reference

DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study

21 January 2018

1 reference

Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction

21 January 2018

1 reference

The association of schizophrenia risk D-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males.

21 January 2018

1 reference

A genetic variant of the serine racemase gene is associated with schizophrenia

21 January 2018

1 reference

No association between the serine racemase gene (SRR) and schizophrenia in a German case-control sample.

21 January 2018

1 reference

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

21 January 2018

1 reference

Glutamate and schizophrenia: beyond the dopamine hypothesis

21 January 2018

1 reference

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

21 January 2018

1 reference

Disposition of D-serine in healthy adults

21 January 2018

1 reference

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

21 January 2018

1 reference

High dose D-serine in the treatment of schizophrenia

21 January 2018

1 reference

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

21 January 2018

1 reference

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo

21 January 2018

1 reference

NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

21 January 2018

1 reference

Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area

21 January 2018

1 reference

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

21 January 2018

1 reference

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

21 January 2018

1 reference

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

21 January 2018

1 reference

The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia

21 January 2018

1 reference

Immunocytochemical localization of D-amino acid oxidase in rat brain

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.12.65

1 reference

27 August 2017

1 reference